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Abstract
Biomethylation is the major pathway for the metabolism of inorganic arsenic (iAs) in many
mammalian species, including the human. However, significant interspecies differences have been
reported in the rate of in vivo metabolism of iAs and in yields of iAs metabolites found in urine. Liver
is considered the primary site for the methylation of iAs and arsenic (+3 oxidation state)
methyltransferase (As3mt) is the key enzyme in this pathway. Thus, the As3mt-catalyzed methylation
of iAs in the liver determines in part the rate and the pattern of iAs metabolism in various species.
We examined kinetics and concentration-response patterns for iAs methylation by cultured primary
hepatocytes derived from human, rat, mice, dog, rabbit, and rhesus monkey. Hepatocytes were
exposed to [73As]arsenite (iAsIII; 0.3, 0.9, 3.0, 9.0 or 30 nmol As/mg protein) for 24 hours and
radiolabeled metabolites were analyzed in cells and culture media. Hepatocytes from all six species
methylated iAsIII to methylarsenic (MAs) and dimethylarsenic (DMAs). Notably, dog, rat and
monkey hepatocytes were considerably more efficient methylators of iAsIII than mouse, rabbit or
human hepatocytes. The low efficiency of mouse, rabbit and human hepatocytes to methylate
iAsIII was associated with inhibition of DMAs production by moderate concentrations of iAsIII and
with retention of iAs and MAs in cells. No significant correlations were found between the rate of
iAs methylation and the thioredoxin reductase activity or glutathione concentration, two factors that
modulate the activity of recombinant As3mt. No associations between the rates of iAs methylation
and As3mt protein structures were found for the six species examined. Immunoblot analyses indicate
that the superior arsenic methylation capacities of dog, rat and monkey hepatocytes examined in this
study may be associated with a higher As3mt expression. However, factors other than As3mt
expression may also contribute to the interspecies differences in the hepatocyte capacity to methylate
iAs.
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Inorganic arsenic (iAs) is biomethylated in a sequence of enzymatically catalyzed reactions
that produce methylarsenic (MAs), dimethylarsenic (DMAs), and trimethylarsenic (TMAs)
species, which contain either trivalent arsenic (AsIII) or pentavalent arsenic (AsV) (Thomas et
al., 2004; Waters et al., 2004a). The extent of methylation and the valency of As determine the
reactivity and toxicity of these metabolites of iAs. Because some toxic or carcinogenic effects
attributed to iAs are likely mediated by its methylated metabolites, understanding the pathway
of methylation of iAs is critical to assessing risk associated with exposure to this metalloid.
Rates and patterns of in vivo methylation of iAs have been extensively examined in laboratory
studies with various species, including humans. These studies show that most mammalian
species rapidly convert iAs to MAs and DMAs. In rodents, TMAs metabolites are also found.
Notably, urinary profiles of metabolites of iAs indicate differences among species in capacity
to form and excrete various arsenicals. For example, MAs represents a greater fraction of
urinary arsenic in humans and rabbits than in other species, e.g., rat or mice (Vahter 1994,
1999). In addition, methylated arsenicals were not detected in urine of iAs-treated marmoset
and tamarin monkeys (Vahter and Marafante, 1985; Zakharyan et al., 1996;), chimpanzees
(Vahter et al., 1995a), and guinea pigs (Healy et al., 1997), suggesting that these species do
not methylate iAs. Tissue distribution of As methylation activity in the methylating species
has not been systematically examined. Methylation of arsenic increases the rate of whole body
clearance; hence, whole body retention of arsenic is higher in non-methylating species than in
species that rapidly methylate arsenic. In the mouse, the highest specific As methylation
activity was found in testes, followed by kidney, liver, and lung (Healy et al., 1998). However,
because of its place in portal circulation and its mass, the liver is generally regarded as the
major site for the methylation of orally administered iAs.
Arsenic (+3 oxidation state) methyltransferase (As3mt) catalyzes all reactions in the pathway
that convert iAs into MAs, DMAs, and TMAs (Waters et al., 2004 a, b; Thomas et al., 2007).
We have previously shown that As3mt is expressed in cultured primary rat and human
hepatocytes (Drobna et al., 2004) and that a knockdown of AS3MT expression by RNA
interference in human hepatocellular carcinoma (HepG2) cells is associated with a proportional
loss of the capacity to methylate iAs (Drobna et al., 2006). Heterologous expression of rat
As3mt in a human uroepithelial cell line that cannot constitutively methylate iAs confers the
capacity to produce the methylated metabolites of iAs (Drobna et al., 2005). Other studies have
shown that sequence polymorphisms of As3mt affect profiles for iAs metabolism in in vitro
methylation systems (Wood et al, 2006), in cell cultures (Drobna et al., 2004), and in human
subjects (Hernandez et al., 2008; Schlawicke Engstrom et al., 2007; Meza et al., 2005).
Similarly, point mutations targeting key cysteine residues altered rates and yields of
methylation of iAs by recombinant mouse, rat, and human As3mt (Li et al., 2005; Fomenko
et al. 2007, Song et al., 2009). In As3mt knockout mice, diminished methylation of orally
administrated arsenate (iAsV) is associated with high retention of arsenic in tissues and a
reduced rate of whole body clearance of arsenic (Drobna et al., 2009). Taken together, these
data suggest that As3mt expression and polymorphism might be key factors affecting rates and
patterns of iAs methylation and, consequently, the distribution and retention of As.
Intracellular reductants that support or modify As3mt activity are likely to be among the factors
that affect capacity of the liver to methylate iAs. Several NADPH-dependent enzymatic
systems that support in vitro activity of recombinant As3mt have been previously identified,
including: (i) thioredoxin (TRx) and TRx reductase (TR); (ii) glutaredoxin, glutathione (GSH)
reductase, and GSH, and (iii) dihydrolipoic acid and TR (Waters et al., 2004a,b; Thomas et al.,
2007). The TRx/TR/NADPH coupled system supported the highest rates of in vitro methylation
of iAsIII by As3mt. GSH was not essential for As3mt activity, but addition of GSH to a reaction
mixture containing As3mt and TRx/TR/NADPH stimulated the overall rate of iAs methylation
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(Waters et al., 2004b; Thomas et al., 2007). The roles of TR and TRx in in vitro methylation
of iAsIII were further examined in the recombinant As3mt assay mixture, in which exogenous
TRx, TR and NADPH were replaced with freshly prepared guinea pig liver cytosol. Although
guinea pig liver is a good source of endogenous reductants, including TRx and TR, iAsIII was
not methylated in an in vitro assay containing guinea pig liver cytosol (Healy et al., 1997).
However, iAsIII was methylated in an in vitro assay system containing guinea pig cytosol and
rat recombinant As3mt (Waters et al., 2004a). Addition of aurothioglucose (ATG), a specific
inhibitor of Se-cysteine-containing enzymes, including TR, sharply reduced MAs and DMAs
production in this reaction mixture. These results indicated that TR (with or without TRx), but
not other reductants present in the guinea pig liver cytosol, was a key co-factor for the As3mt-
catalyzed methylation of iAsIII.
In the work reported here, we have examined differences in the metabolism of iAs in primary
cultured hepatocytes from six species (human, rat, mouse, rabbit, dog, and macaque rhesus).
The use of cultured hepatocytes is consistent with role of the liver as a primary site for the
methylation of arsenicals. This work examined the roles of As3mt expression and protein
structure, TR activity, and GSH concentration in differences among species in capacity of
hepatocytes for iAs methylation. We found that hepatocytes from rat, macaque, and dog had
much greater capacities to methylate iAs than do hepatocytes from human, mouse or rabbit.
Neither TR activity nor GSH concentration in hepatocytes differed significantly between these
two groups of species. Differences in the methylation capacities of hepatocytes from different
species could not be rationalized by differences in the predicted amino acid sequences of this
protein. However, As3mt protein levels were higher in hepatocytes from the high-methylator
group than the lower methylator group. Thus, As3mt expression might be a key factor in
interspecies differences in iAs metabolism by primary hepatocytes examined in this study.
Materials and Methods
Chemicals
A carrier-free [73As]arsenous acid (Brookhaven National Laboratory, Upton, NY) was reduced
to arsenite ([73As]iAsIII) in a reaction with a metabisulfate-thiosulfate reagent (Reay and Asher,
1977). Sodium arsenite, 99% pure (Sigma; St. Louis, MO), was used as a carrier for [73As]
iAsIII solutions. All other chemicals and reagents were of the highest grade available.
Cell culture
Freshly prepared suspensions of primary hepatocytes isolated from livers of a 7-week old male
CD-1 mouse, 10-week old male Sprague-Dawley rat, 9-month old male Beagle dog, 4-month
old female New Zealand White rabbit, 5-year old male Rhesus macaque, and a 56-year old
woman were obtained from CellzDirect (Pittsboro, NC). Following the CellzDirect
instructions, hepatocytes were plated on collagen-I coated 12- and 6-well plates (Becton-
Dickinson) at respective densities of 0.75 and 1.5 × 106 viable cells/well for all animal species
except mouse. The plating densities for mouse hepatocytes were 0.5 and 1.5 × 106 viable cells/
well for 12- and 6-well plate, respectively. Human hepatocytes that are smaller in size than
hepatocytes for the other species were plated in 24-well plates at 0.5 × 106 viable cells per
well. The plating medium was William’s medium E (Sigma) containing 10% certified fetal
bovine serum (FBS; Gibco), 2 mM glutamine (Sigma), 100 units/mL penicillin (Sigma), 100
µg/mL streptomycin (Sigma), 0.5 µM dexamethasone (Sigma), 5 µg/ml bovine insulin
(Sigma), 5 µg/ml human transferrin (Sigma), and 5 ng/ml sodium selenite (Sigma). The same
medium without FBS was used to culture attached hepatocyte monolayers for 3 to 5 days at
37 °C in a 95% air/5% CO2 atmosphere. The medium was changed daily.
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Hepatocytes from each species were used in two experimental designs. The first design focused
on time course of MAs and DMAs production from iAsIII over a 24-hour incubation period;
the second examined 24-hour yields of MAs and DMAs in response to various concentrations
of iAsIII. To control for differences among species in number of cultured cells, concentrations
of iAsIII were adjusted for cellular protein. Protein concentrations were determined shortly
before the treatment with iAsIII using hepatocytes cultured in the same plates that were prepared
for the treatment. The average protein concentration for 3 wells was used to determine the
amount of iAsIII needed for the treatment. For time course experiments, cells were exposed to
0.3 nmol [73As]iAsIII per milligram of protein and media and cells were harvested after 3, 6
and 24 hours. For concentration-response experiments, cells were exposed to 0.3, 0.9, 3.0, 9.0
or 30 nmol [73As]iAsIII per milligram of protein and media and cells were harvested after 24
hours. Hepatocytes cultured in 12-well plates (24-well plates for human donor) were used in
both types of experiments.
Analysis of iAs metabolites
Radioactivity associated with harvested cells and culture media were measured using Minaxi
5000 gamma counter (Packard Instruments Co., Downers Grove, IL). Radiolabeled metabolites
of [73As]iAsIII were analyzed in CuCl extracts from cells and media by ion-exchange thin-
layer chromatography (TLC) (Styblo et al., 1995a, 1995b, 1996). Radioactivity on TLC plates
was monitored with a FLA 2000 imaging system (FujiFilm, Stamford, CT). Because CuCl
extracts were oxidized with hydrogen peroxide before TLC separation, this technique could
not determine the original oxidation states of As in separated metabolites. Thus, the As species
detected by TLC were referred to generically as iAs (i.e., iAsIII + iAsV), MAs (i.e., MAsIII +
MAsV), and DMAs (i.e., DMAsIII + DMAsV).
RT-PCR, DNA sequencing and multiple protein sequence alignment
As3mt mRNA levels were determined by touch-down PCR as previously described (Drobna
et al., 2004). Briefly, total RNA was extracted using TRIzol reagent (Life Technology Inc.,
Gaithersburg, MD). Extracted RNA was treated with DNase (Promega, Madison, WI) and
purified using an RNaesy Minikit (Qiagen, Valencia, CA). One microgram of RNA was reverse
transcribed using SuperScript II reverse transcriptase and random primers (Invitrogen,
Carlsbad, CA). An aliquot of cDNA representing 50 ng of RNA and As3mt primers specific
for a conserved as3mt sequence were used for the PCR step. The primer sequences and the
complementary nucleotide sequences in As3mt mRNA from rat, mouse, human, dog, and
macaque are shown in Table 1. For all species examined, the PCR step amplified a 477-bp
DNA fragment. The DNA fragment for each species was sequenced in both forward and reverse
directions at the UNC Chapel Hill Automated DNA Sequencing Facility. The sequences of the
DNA fragments were then blasted against as3mt sequences available from GenBank, including
that for rat (Rattus norvegicus: NM_080890), human (Homo sapiens: NM_020682;), and
mouse (Mus musculus: NM_020577), and also against dog and rhesus as3mt sequences (Canis
familiaris: XM_543995; Macaca mulatta: XM_001113391) predicted by the automated
computational analysis GNOMON. ExPasy proteomics tools (Swiss Institute of
Bioinformatics; www.us.expasy.org) were used to translate the as3mt nucleotide sequences
into the corresponding amino acid sequences. A multiple protein sequence alignment was
generated using a EMBL-EBI ClustalW program (European Bioinformatics Institute,
European Molecular Biology Laboratory; www.ebi.ac.uk/clustalw).
Immunoblot analysis
Protein extracts for immunoblot analyses were prepared from hepatocytes cultured in 6-well
plates (24-well plates for the human cells). Cells were lysed in RIPA buffer containing 50 mM
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Tris-HCl (pH 7.4), 1% NP-40, 150 mM NaCl, 0.25% Na-deoxycholate, 1 mM NaF, 1 mM
EDTA, and protease and phosphatase inhibitors (Drobna et al., 2005). Cell lysates were spun
at 10,000 × g and supernatants were stored at −80° C until analyzed. Proteins in cell lysates
were separated by 10% SDS-PAGE and transferred to polyvinylidene difluoride Immobilon-
P membranes (Millipore Corp., Bedford, MA). For As3mt analysis, the membranes were
probed with a rabbit anti-serum raised against the recombinant rat As3mt (Alpha Diagnostic
International, San Antonio, TX) or with a rabbit polyclonal antibody directed against a 20-
amino acid fragment (341–360) of human AS3MT (Wood et al, 2006) (gift from Professor
R.M. Weinshilboum, Mayo Clinic College of Medicine, Rochester, MN). β-actin was detected
using a mouse monoclonal antibody (Abcam, Cambridge, MA). The antigen-antibody
complexes were visualized after incubation with the corresponding HRP-conjugated antibody
(Santa Cruz Biotechnology, Santa Cruz, CA) by enhanced chemiluminescence detection
(Amersham, Biosciences, Pittsburgh, PA) using a computerized GeneGnome imaging system
(Syngene, Frederick, MD).
Biochemical analyses
Intracellular concentrations of GSH and GSH disulfide (GSSG) were determined in cell lysates
prepared in 5% sulfosalicylic acid, using a GSSG reductase-coupled recycling assay (Styblo
et al. 1997). TR activity was measured in cell lysates prepared in 0.1 M Na/K phosphate-0.5%
Triton ×100 buffer (pH 7.4), using 5,5’-dithiobis(2-nitrobenzoic acid) as a substrate (Lin at al.
1999). Bicinchoninic acid assay kit (Sigma) was used to determine protein concentrations in
hepatocyte monolayers before treatment with [73As]iAsIII and in hepatocyte lysates or extracts
prepared for various biochemical analyses. Calibration curves for this assay were prepared
using bovine serum albumin as a standard.
Statistical analysis
One-way ANOVA and Tukey’s multiple comparison test were used to analyze differences
between species. Differences between hepatocytes from species with low (human, mouse and
rabbit) and high (rat, macaque and dog) capacities to methylate iAs were analyzed using
unpaired t-test (GraphPad Software Inc., San Diego, CA). Nonparametric Spearman
correlation was used to analyze associations between the rate or pattern of iAs methylation and
the concentration or activity of the As3mt co-factors in cultured hepatocytes. Differences or
correlations with p<0.05 were considered statistically significant.
Results
Kinetics of iAs methylation: MAs and DMAs yields
To examine interspecies differences in rates and patterns of iAs methylation, we exposed
primary cultures of hepatocytes isolated from human, rat, mouse, dog, rabbit, and macaque to
a low concentration of [73As]iAsIII (0.3 nmol/mg prot.) and quantified radiolabeled MAs and
DMAs in cells and in medium after 3-, 6- or 24-hours of exposure (Fig. 1). The kinetics of
iAsIII methylation by dog, macaque, and rat hepatocytes were characterized by fast production
of DMAs over the first 3 to 6 hours. After 24 hours, 90 to 97% of total As in these cultures
was DMAs; MAs was a minor metabolite (0.5 to 1.5% of total As). In contrast, the rates of
DMAs production were much lower in cultures of rabbit, mouse, and human hepatocytes. Time
courses for DMAs production for these three species were almost linear over the 24-hour
interval. At 24 hours, DMAs accounted for 38 to 79% of total As in the cultures. During the
first 6 hours, MAs yields were similar to those for DMAs. After 24 hours, 11 to 12% of total
As in cultures was MAs. For all time points, DMAs/MAs ratios were significantly higher in
cultures of dog, macaque, and rat hepatocytes compared to cultures of hepatocytes from rabbit,
mouse, or human. After 24 hours, DMAs/MAs ratios in faster methylating hepatocyte cultures
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ranged from 60 (macaque) to 193 (rat) and in slower methylating cultures the ratios ranged
from 3.4 (human) to 6.7 (rabbit).
Kinetics of iAs methylation: Cellular retention of As species
The sum of all arsenicals (iAs + MAs + DMAs) retained in hepatocytes exposed to 0.3 nmol
[73As]iAsIII/mg protein significantly changed over the 24-hour treatment period. Notably, the
dynamics of the cellular retention differed between faster methylating dog, macaque and rat
hepatocytes and slower methylating rabbit, mouse and human hepatocytes (Fig. 2).
Hepatocytes from all six species rapidly accumulated 73As during the first 3 to 6 hours of the
exposure. Between 3 and 24 hours, levels of 73As in slower methylating hepatocytes remained
high or further increased. In contrast, 73As initially accumulated in hepatocytes from faster
methylating group was released into the medium. After 24 hours, the faster methylating
hepatocytes retained from 8 to 43 pmol As/mg prot. as compared to 59 to 90 pmol As/mg prot.
for the slower methylating hepatocytes.
Concentration dependence of MAs and DMAs yields
To examine for the concentration dependency of iAs methylation, hepatocyte cultures were
exposed to [73As]iAsIII at final concentrations of 0.3, 0.9, 3.0, 9.0, or 30 nmol/mg protein. MAs
and DMAs yields were determined in cells and in medium after a 24-hour exposure (Fig. 3).
In cultures of faster methylating hepatocytes from dog, macaque, and rat, DMAs was the major
methylated metabolite over the range of iAsIII concentrations of 0.3 to 9.0 nmol/mg prot.
However, DMAs production was reduced in cultures exposed to 30 nmol iAsIII. At the highest
exposure level of 30 nmol/mg prot., average MAs yield equaled DMAs yield in hepatocytes
from macaque and was higher than DMAs yield in hepatocytes from dog and rat. DMAs was
also the major methylated metabolite in slower methylating hepatocytes from rabbit, mouse,
and human exposed to low concentrations of 0.3 or 0.9 nmol iAsIII/mg prot. At higher iAsIII
concentrations, MAs was the major metabolite as DMAs production decreased or remained
unchanged. Production of both MAs and DMAs was inhibited in cultures of human hepatocytes
exposed to 9 or 30 nmol iAsIII/mg prot. and in cultures of mouse hepatocytes exposed to 30
nmol iAsIII/mg protein. Human hepatocytes were the least efficient methylators of iAsIII at any
exposure level.
Concentration dependence of iAs methylation rates
Average rates of iAsIII methylation were calculated for each exposure level as pmol of methyl
groups transferred to iAsIII per hour per milligram of protein, using MAs and DMAs yields
after a 24-hour exposure (Fig. 4). For each exposure level, methylation rates were consistently
higher in cultured dog, macaque, or rat hepatocytes than in cultured rabbit, mouse, or human
hepatocytes. Unlike other species, rabbit hepatocytes displayed a low and unchanged rate of
iAs methylation at all exposure levels. Methylation rates increased proportionally with the
initial concentration of iAsIII for dog, macaque, or rat hepatocytes exposed to up to 9 nmol
iAsIII/mg protein; rates were proportional for rabbit, mouse, or human hepatocytes exposed to
up to 3 nmol iAsIII/mg protein. Initial slopes for concentration-methylation rate curves for dog,
macaque, or rat hepatocytes were greater than those for rabbit, mouse, or human hepatocytes.
Exposure of rat hepatocytes to 30 nmol iAsIII/mg protein sharply decreased the methylation
rate, but did not affect the methylation rate for dog hepatocytes. The iAsIII methylation rate
decreased from peak values in cultured human hepatocytes exposed to 9 or 30 nmol iAsIII/mg
protein and in cultured mouse hepatocytes exposed to 30 nmol iAsIII/mg protein. Rates of iAs
methylation by macaque hepatocytes rose proportionally over the entire range of iAsIII
concentrations.
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Concentration dependence of arsenical distribution between hepatocytes and medium
The level of iAsIII in medium affected both concentrations and proportions of As species
retained by hepatocytes after 24-hour exposures (Fig. 5). At low exposures levels (0.3 to 3
nmol iAsIII/mg protein), DMAs was the major arsenical in dog, macaque, or rat hepatocytes,
accounting for 46 to 95% of total cellular As. Over this range, MAs accounted for less than
16%. In contrast, MAs accounted for 18 to 42% of total As retained by rabbit, mouse, or human
hepatocytes and iAs accounted for 19 to 63%. At these exposure levels, dog, macaque, or rat
hepatocytes retained less total As (i.e., iAs + MAs + DMAs) than did rabbit, mouse, or human
hepatocytes. At higher exposure levels (9 and 30 nmol iAsIII/mg protein) concentration of
DMAs in dog, macaque, or rat hepatocytes decreased and concentrations of MAs and iAs
increased. Rabbit, mouse, or human hepatocytes exposed to 9 or 30 nmol iAsIII/mg protein
retained almost exclusively iAs; the concentration and percentage of MAs decreased in a
concentration-dependent manner. At the lowest exposure level (0.3 nmol iAsIII/mg protein),
DMAs was the major arsenical found in media of all cultures (Fig. 6). At the higher exposure
levels, DMAs concentrations in media gradually decreased. However, DMAs concentrations
in medium were consistently higher in dog, macaque and rat hepatocyte cultures as compared
to the cultures of hepatocytes from rabbit, mouse, or human.
As3mt expression
Expression of As3mt in cultured hepatocytes before exposure to iAsIII was examined at the
levels of mRNA and protein (Fig. 7). As3mt mRNA was detected by RT-PCR in hepatocytes
from all six species (Fig. 7a). The first immunoblot analysis using rabbit anti rat recombinant
As3mt antiserum detected immunoreactive protein in human, mouse, rabbit, macaque, and rat
hepatocytes but not in dog hepatocytes (Fig. 7b). The second immunoblot analysis used a rabbit
polyclonal anti-human AS3MT antibody (1:5,000 dilution). Here, As3mt protein was detected
in hepatocytes from rabbit, macaque, rat and dog, but not in hepatocytes from mouse (Fig. 7c).
This antibody was not used for analysis of AS3MT in human hepatocytes due to a limited
number of the cells available for this study. To increase assay sensitivity, the immunoblot
analysis of As3mt in mouse hepatocytes was repeated using the rabbit anti-human AS3MT
antibody diluted 1 to 2,000. Under these conditions, a weak signal for As3mt protein was
detected (Fig. 7d). The As3mt immunoblot signals in hepatocytes from the six species were
then normalized to the corresponding immunoblot signals of β-actin (Fig. 7e). The normalized
values for the two different anti-AS3MT antibodies show that the macaque and rat and,
possibly, the dog hepatocytes contained higher levels of As3mt than did the hepatocytes from
rabbit, mouse or human (Fig. 7b/e and Fig. 7c/e).
TR activity and GSH and GSSG concentrations
Mono- and dithiol compounds are modulators of the catalytic activity of As3mt. TR is required
for As3mt catalysis of iAs methylation in in vitro assays and GSH modulates MAs and DMAs
yields in in vitro TR-dependent As3mt-catalyzed methylation of iAsIII (Waters et al., 2004ab;
Thomas et al., 2007). Here, TR activity and GSH and GSSG concentrations were determined
in cultured hepatocytes from the six species before exposures to iAsIII (Table 2). No statistically
significant correlations were found between rates of iAsIII methylation and TR activity, GSH,
or GSSG concentration regardless of the exposure level (data not shown). Categorizing
hepatocytes into faster and slower methylation groups as described above found no correlation
between methylation rate and TR activity or between methylation rate and GSH or GSSG
concentrations (data not shown).
Discussion
The capacity of cultured cells to methylate iAs can be characterized by the rate of conversion
of iAs to MAs and DMAs and by relative yields of DMAs and MAs or by the DMAs/MAs
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ratio at a range of low to high exposures to iAs. Using these criteria, we have previously shown
that at the same substrate concentrations cultured rat primary hepatocytes methylated iAsIII
much faster than did primary human hepatocytes from several donors (Styblo et al., 1999). In
addition, methylation of iAsIII by human hepatocytes, specifically DMAs production, was
found to be sensitive to substrate inhibition, resulting in DMAs/MAs ratios < 1 even in
hepatocytes exposed to relatively low initial concentrations of iAsIII. At equal iAsIII
concentrations, rat hepatocytes produced DMAs as the major metabolite and DMAs/MAs
ratios were consistently higher than those in human hepatocytes. We have also shown that the
capacity of primary human hepatocytes to methylate iAsIII varies dramatically among donors
(Drobna et al., 2004, 2010). The highest (maximal) methylation rates were usually recorded at
iAsIII concentrations of 3 to 30 nmol/mg protein and ranged from about 2 to 30 pmol CH3 per
milligram of protein per hour.
The main goal of this study was to compare metabolic profiles for iAsIII in primary cultures
of hepatocytes from a human and from several mammalian species, some of which have
previously been used in studies examining either toxicity or metabolism of iAs. We found that
rates and patterns of iAsIII methylation by primary hepatocytes from one group of species
(Sprague-Dawley rat, Rhesus macaque and Beagle dog) differed markedly from those in the
other group of species (human, CD-1 mouse, and New Zealand White rabbit). Methylation of
iAsIII by hepatocytes from the first group of species was characterized by high methylation
rates, high DMAs/MAs ratios, fast clearance of DMAs from cells, and relative insensitivity to
the inhibition of methylation by high iAsIII concentrations. In contrast, the second group of
species exhibited low methylation rates, low DMAs/MAs ratios, delayed clearance of As
species, and marked inhibition of the methylation reactions, especially DMAs production, by
moderate iAsIII concentrations. Notably, the rates of iAs methylation by human hepatocytes
used in this study exceeded the methylation rates reported for human hepatocytes in our
previous studies (Drobna et al., 2004, 2010). The maximal methylation rate of 49 pmol CH3/
mg prot. per hour was found in human hepatocytes exposed to 3 nmol iAsIII/mg prot. However,
consistent with our previous findings, even this relatively high methylation rate was almost 7
times lower that the maximal methylation rate recorded for rat hepatocytes exposed to 10 nmol
iAsIII/mg prot: 340 pmol CH3/mg prot.
Complete predicted amino acid sequences for As3mt from human, mouse, rat and Rhesus
monkey and the incomplete predicted amino acid sequence for dog As3mt were compared to
see if sequences provide any insights into species differences in capacity or pattern of As
methylation (Table 3). This comparison also included a portion of a predicted amino acid
sequence for rabbit As3mt which we obtained by translating the nucleotide sequence of a 477-
base DNA fragment generated in the present study by RT-PCR (Fig. 7a). The multiple protein
sequence alignment of the full length of As3mt using Clustal-W program
(www.ebi.ac.uk/clustalw) showed high degrees of sequence homology among all species. The
highest degree of homology was found between the human and macaque As3mt sequences
(Table 4). In contrast, the rate and pattern of iAs metabolism by primary hepatocytes from
these two species were markedly different. Notably, sequences of motifs commonly found in
non-DNA methyltransferases (Kagan and Clarke, 1994) were highly conserved in these six
species. In addition, analogs of Cys157 and Cys207 that are essential for the activity of mouse
As3mt (Fomenko et al., 2007) are found in As3mt sequences for the other 5 species examined
in this study, including the fragment of rabbit As3mt. Thus, no major differences in predicted
amino acid sequences in As3mt from these species can be invoked as a basis for differences
in rates of formation or patterns of metabolites produced by hepatocytes exposed to iAsIII.
As3mt plays a key role in the methylation of iAs in hepatic cells (Drobna et al., 2006).
Therefore, the rate and pattern of iAsIII methylation by hepatocytes depend in part on As3mt
expression. Results of our non-quantitative RT-PCR confirm that As3mt mRNA is present in
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hepatocytes from all six species examined in this study. We also performed a semiquantitative
immunoblotting to compare As3mt protein levels in hepatocytes from different species. To
account for probable interspecies variation in As3mt structures, we used two immunoreagents,
an antiserum raised against recombinant rat As3mt and a polyclonal antibody against a 20-
amino acid fragment (341–360) of human AS3MT (Wood et al., 2006), for detection and
quantitation of As3mt. Notably, the human AS3MT sequence used for antibody production is
highly conserved in rat, dog, macaque, and mouse As3mt (Table 3). (A corresponding sequence
in rabbit As3mt has not been determined.) Results of two independent immunoblot analyses
indicated that the hepatocytes from macaque, Sprague-Dawley rat, and possibly, from Beagle
dog contained higher levels of As3mt protein than did hepatocytes from human, CD1 mouse
or New Zealand White rabbit. Molecular masses of the dog, macaque and rabbit As3mt have
not yet been determined; however, electrophoretic mobilities of the immunoreactive protein
bands from the corresponding hepatocytes (Fig. 7c) suggests the molecular masses of dog,
macaque, and rabbit As3mt to be similar to those of As3mt from the other species.
The metabolism of iAs in hepatocytes may also be affected by availability of intracellular
reductants, specifically TR and GSH that are known to support or modulate in vitro activity of
recombinant As3mts (Waters et al., 2004a, 2004b). However, results of this study found no
statistically significant correlations between TR activity or GSH concentrations and rates of
iAsIII methylation by primary hepatocytes from the six species. Thus, our data suggest the
differences in rates and patterns of iAsIII methylation by hepatocytes from these species to be
mainly due to differences in As3mt expression, specifically in the As3mt protein levels. In
should be emphasized that hepatocytes from a single animal from each of the five animal
species were examined in this study. However, inter-animal variations are possible within each
of these animal species, even within the inbred mouse or rat strain. Thus, the patterns of iAs
metabolism by primary hepatocytes as described in this study are not necessarily representative
of the entire species. In addition, factors other than As3mt expression may also contribute to
the interspecies differences in the capacity of primary hepatocytes to methylate iAsIII and to
retain metabolites of iAs in cells. Identification of these factors is the goal of our future studies.
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Kinetics of iAsIII methylation by primary cultures of hepatocytes isolated from dog, macaque,
rat, rabbit, mouse, and human. The yields of MAs (○) and DMAs (●) produced by hepatocytes
exposed to [73As]iAsIII (0.3 nmol/mg prot.) for 3, 6 and 24 hours (Mean ± SD, n = 3).
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Cellular retention of total arsenic by dog, macaque, rat, rabbit, mouse, and human hepatocytes
as a function of the exposure time. Hepatocytes were exposed to [73As]iAsIII (0.3 nmol/mg
prot.) and the radioactivity associated with cells was measured after 3, 6 and 24 hours (Mean
± SD, n = 3).
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The concentration-response patterns for iAsIII methylation by dog, macaque, rat, rabbit, mouse,
and human hepatocytes. The yields of MAs (○) and DMAs (●) after 24-hour exposures to
[73As]iAsIII at the initial concentrations of 0.3, 0.9, 3, 9, and 30 nmol iAsIII/mg protein (Mean
± SD, n = 3).
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The rates of iAsIII methylation by dog, macaque, rat, rabbit, mouse, and human hepatocytes
as a function of the initial concentration of [73As]iAsIII in the culture. The methylation rates
(pmol CH3/mg protein per hour) are shown for cells exposed for 24 hours to 0.3, 0.9, 3, 9, and
30 nmol iAsIII/mg protein (Mean ± SD, n = 3).
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Intracellular concentrations of the metabolites of iAsIII in dog, macaque, rat, rabbit, mouse,
and human hepatocytes as a function of the initial concentration of [73As]iAsIII in the culture.
The intracellular concentrations of iAs, MAs, and DMAs normalized for cellular protein
(Mean, n = 3) are shown for cells exposed for 24 hours to 0.3, 0.9, 3, 9, and 30 nmol iAsIII/mg
protein.
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Concentrations of the metabolites of iAsIII in culture medium of dog, macaque, rat, rabbit,
mouse, and human hepatocytes as a function of the initial concentration of [73As]iAsIII in the
culture. The concentrations of iAs, MAs, and DMAs normalized for cellular protein (Mean, n
= 3) are shown for cells exposed for 24 hours to 0.3, 0.9, 3, 9, and 30 nmol iAsIII/mg protein.
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Expression of As3mt in cultured primary hepatocytes from dog, macaque, rat, rabbit, mouse,
and human: Analysis of As3mt mRNA by RT-PCR (a); As3mt protein detected by rabbit anti-
serum against recombinant rat As3mt (b); As3mt protein detected by rabbit polyclonal antibody
against human AS3MT diluted 1:5,000 (c) and 1:2,000 (d); immunoblot analysis of β-actin
(e); As3mt protein level detected by the rabbit anti-serum normalized for β-actin (b/e); As3mt
protein levels detected by the rabbit polyclonal antibody normalized for β-actin (c/e).
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Table 1
PCR primers and the corresponding nucleotide sequences in As3mt mRNA from rat, mouse, human, dog, and
macaque*.
FORWARD REVERSE
PCR Primers ATTTTGGATCTGGGCAGTGGGAGT TCTGCCCTCCACGTTTGGTCACT
Rat as3mt ATTTTGGATCTGGGCAGTGGGAGT TCTGCCCTCCACGTTTGGTCACT
Mouse as3mt ATTTTGGATCTGGGCAGTGGGAGT TCTGCCCTCCACGTTTGGTCACT
Human as3mt ATTTTGGATCTGGGTAGTGGAAGT TCTGCCCTCCACGTTTGGTCACT
Dog as3mt ATTTTGGACCTGGGCAGTGGAAGT TCTGCCCTCCACGTTTAGTCACT
Macaque as3mt ATTTTGGATCTGGGTAGTGGAGGT TCTGCCCTCCACGTTTGGTCACT
Rabbit as3mt N/A** N/A
*
Mismatched nucleotides in as3mt sequences are underlined and bolded.
**
Nucleotide sequence of rabbit as3mt is not available.
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Table 3
Clustal-W 2.0.5 multiple protein sequence alignment.
I, I’, II, and III: non DNA-methyltransferase sequence motifs.
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